Humans 
INTRODUCTION
than in family members who did not carry mutations in ANGPTL3, but no significant differences in EL activity were observed.
In contrast, the mechanism responsible for the lower plasma levels of LDL-C associated with ANGPTL3 deficiency remains enigmatic. Plasma LDL-C levels are determined by the relative rates of production and clearance of LDL (18) . LDL is produced in the circulation from VLDL, a TG-rich lipoprotein assembled in the liver. The surface of VLDL is decorated with multiple proteins, including several copies of apolipoprotein (Apo)E as well as a single copy of ApoB. Following lipolysis by LPL,
VLDL and its metabolic intermediate, intermediate density lipoprotein (IDL), have two possible fates:
clearance by the liver or further metabolism to LDL. Hepatic uptake of VLDL remnants (and intestinederived chylomicron remnants) is mediated by ApoE, which is bound by LDLRs (19) and by LDL receptor related protein 1 (LRP1) (20) or by proteoglycans (syndecan 1) (21) . The remaining VLDL remnant particles mature into LDL, which is removed from the blood primarily by LDLR-mediated endocytosis in the liver. Inactivation of ANGPTL3 in mice by gene targeting or by anti-ANGPTL3 antibodies reduces plasma cholesterol levels in mice lacking functional ApoE (22) or LDLR (23). These data indicate that ANGPTL3 lowers LDL by a mechanism that is independent of both a major ligand for receptor-mediated clearance of lipoproteins and the major receptor that mediates clearance of circulating LDL.
To investigate the mechanism by which ANGPTL3 deficiency lowers plasma LDL-C levels, we used REGN1500, a fully human monoclonal antibody that binds with high affinity to both human and mouse ANGPTL3, to inactivate ANGPTL3 in mice with genetically defined defects in the major pathways through which circulating lipoproteins are cleared. Here we report the effect of ANGPTL3 inactivation on the synthesis and clearance of LDL in mice. 
MATERIALS AND METHODS

Materials
REGN1500, a fully human monoclonal antibody, was derived using Regeneron's Velocimmune® technology platform (companion paper). An isotype-matched antibody with irrelevant specificity was used as control. All other chemicals were purchased from Sigma unless otherwise indicated.
Studies in mice
Wild-type, Apoe -/-, & Ldlr -/-C57BL/6J mice were purchased from Jackson Laboratory. Mice deficient in syndecan 1 (Sdc1 -/-) were provided by P. Park (Harvard University, Cambridge, MA) (24) .
Liver-specific Lrp1 knockout (KO) mice were from Joachim Herz (UT Southwestern, Dallas, TX) (25) .
Ldlr -/-;Lrp1
-/-mice were generated by crossing liver-specific Lrp1 -/-mice with Ldlr -/-animals. Angptl3
-/-mice were developed by homologous recombination using Regeneron's Velocigene technology (26) .
All Angptl3 -/-mice were on a mixed background (25% of 129/Sv and 75% of C57BL/6). F 1 heterozygous mice were bred to generate wild-type (WT) and KO mice, which were used for all experiments. All animal procedures were conducted in compliance with protocols approved by the University of Texas Southwestern Medical Center Animal Care and Use Committee (IACUC) and in accordance with federal animal welfare policies and regulations. Mice were fed a chow diet (4% fat and 0.04% cholesterol) (Teklad 7001) and maintained on a 12-h light (7 am-7 pm)/ 12-h dark (7 pm-7 am) cycle unless otherwise indicated. Fat free diet was obtained from MP biomedical, LLC (901683). REGN1500 and isotype
Nonesterified fatty acids (NEFAs) were measured by use of an HR Series NEFA-HR Kit (Wako Diagnostics).
Lipoprotein profiling
Plasma lipoprotein particles were size fractionated by fast performance liquid chromatography (FPLC) using a Superose 6 column (GE Healthcare) and the cholesterol and TG content of each fraction was measured enzymatically (Infinity; Thermo Scientific) as described (27) .
VLDL production
Mice were injected via the tail vein with Triton WR1339 (500 mg/kg) (Tyloxapol, SigmaAldrich) in 200 l of sterile saline to inhibit the hydrolysis and clearance of plasma VLDL (28) . At the indicated time points, blood samples were collected in EDTA-coated tubes from the tail vein and the TG content was measured enzymatically. In a parallel set of antibody-treated mice, plasma samples collected at 90 min were pooled and subjected to FPLC fractionation. A total of 30 l of each fraction (total volume of 300 l) was subjected to immunoblotting using a rabbit anti-mouse ApoB polyclonal antibody that was developed in our laboratory.
ApoB secretion
ApoB secretion rates were measured as described previously (29 The films were scanned using a HP Scanjet 5590 and quantified using ImageJ (http://rsbweb.nih.gov/ij/).
The intensity of each band was corrected for background using a blank from the same film. In a separate gel, 10 l of each sample was subjected to immunoblot analysis with an anti-ApoB polyclonal antibody.
The immunoblots were scanned with an Oddyssey fluorescent imaging system (Li-Cor) to quantify the intensity of the ApoB bands.
LDL and-VLDL clearance
LDL was isolated by sequential ultracentrifugation (30) from Ldlr -/-mice fed a high-cholesterol (1%) diet for two weeks and labeled with 125 I using the iodine monochloride method. A total of 15 g of 125 I-LDL (specific activity: 170 cpm/ng) in 10 mM TrisCl, pH 7.4, 150 mM NaCl and 0.2% BSA was injected into tail veins of mice treated with REGN1500 or control antibody. Blood samples were collected from the tail vein at 2 min, 10 min, 30 min, 1 h, 2 h and 4 h after the injection. Plasma was isolated from each sample and radioactivity was measured by gamma counting (10 l aliquot of plasma).
A second 10 l aliquot was precipitated with isopropanol and the supernatant was counted. ApoB labeling was calculated as the difference between total counts and the supernatant counts. The amount of Beta-VLDL was isolated by ultracentrifugation from rabbits fed a chow diet containing 2% cholesterol for 10 days. The particles were radiolabeled with 125 I using the iodine monochloride method (31) . A total of 15 g of 125 8 injection. The mice were then sacrificed and perfused with 10 ml of cold saline through the left ventricle before the tissues were collected. The radioactivity of each tissue was quantified in a -counter (total uptake). A sample was also subjected to lysis using RIPA buffer (50 mM TrisCl, pH 7.4, 0.1% SDS, 1%
Trition-100, 0.1% sodium deoxycholate, 250 mM NaCl, 20 mM NaF) plus protease inhibitor cocktail (Roche) and the proteins were precipitated with acetone. The supernatant was subjected to -counting.
Tissue 125 I-ApoB uptake was calculated by subtracting the counts in the supernatant from the total counts.
Data was expressed as percentage uptake of total injected dose per 100 mg of tissue. Plasma samples were processed as described for the LDL clearance experiment.
Fatty acid uptake
Tritiated bromopalmitate and 14 C-palmitate was complexed with fatty acid free BSA (Sigma) as described fatty acid free BSA (Sigma) as described (32) . Briefly, 10 ci of drop-wise to 0.6 ml of 4% fatty acid-free BSA and stirred continuously. Normal saline was added up to a final volume of 2 ml. A total of 200 l was injected into each mouse via the tail vein and 5 min later, the mice were perfused with 10 ml of cold saline and sacrificed. Tissues were collected, lysed and the radioactivity quantitated as described (26) .
Fatty acid infusion
On day 1, a cannula was placed in the jugular vein. From day 2 to day 5, the mice were fasted from 5:00 pm to 7:00 am and refed from 7:00 am to 5:00 pm. On day 5, mice were refed at 7:00 am and at 9:00 am were injected with control antibody or REGN1500. Two h after antibody treatment, 3 Hpalmitate was infused into the mice as described (32) . Briefly, 50 ci of g body weight. Blood was sampled every min from the tail vein during the infusion period and twice after infusion. Plasma was isolated and subjected to scintillation counting.
Transcriptome sequencing
Male WT and Angptl3 -/-mice (age 12 weeks, n=4-6/group) were entrained to a synchronized feeding schedule (12-h fasting and 12-h feeding) for 3 days and killed at the end of the dark cycle of the third day. Livers were harvested and total RNA was extracted using a Qiagen RNeasy Midi kit. RNA samples were pooled and subjected to whole transcriptome shotgun sequencing as described (26) .
Fatty acid synthesis
Feeding was synchronized for 5 days prior to measurement of fatty acid synthesis in the liver and kidney (fasting, light cycle: 9:00 am-9:00 pm and refeeding, dark cycle: 9:00 pm-9:00 am). Fatty acid synthesis was measured at the end of the refeeding cycle using H into fatty acids was quantitated as previously described (33) .
Fatty acid oxidation
Wild-type mice were treated with either REGN1500 or control antibody (10 mg/kg). Four days after treatment, primary hepatocytes were isolated from the mice at 9:00 am. XF-24 cell culture plates (Seahorse Bioscience) were coated with rat tail collagen (Sigma) and primary hepatocytes were seeded at a density of 2 × 10 4 cells per well in five replicates for each mouse. Cells were allowed to adhere for five hours and then oxygen consumption was measured as described previously (34) . 
RESULTS
As a first step towards investigating the mechanism by which inactivation of ANGPTL3 lowers plasma LDL-C levels, we used REGN1500 to inactivate circulating ANGPTL3 in mice with defects in the major clearance pathways for LDL and its biosynthetic precursors: LDLR, the predominant vehicle for the clearance of LDL (19) REGN1500 is a monoclonal antibody developed against human ANGPTL3 that binds mouse, rat and monkey ANGPTL3 with a similar affinity. A full description of REGN1500 is provided in the companion paper (companion paper).
Immunological inactivation of ANGPTL3 lowers plasma cholesterol levels in the absence of LDLR or hepatic LRP1
Previously, Lee et al. (23) showed that antibody-mediated inactivation of ANGPTL3 decreases plasma cholesterol levels in Ldlr -/-mice, thus indicating that ANGPTL3 inhibition lowers LDL-C levels independently of the LDLR. Consistent with these earlier findings, REGN1500 lowered cholesterol and TG by 33% and 40%, respectively, in Ldlr -/-and WT animals ( Quantitative immunoblot analysis was performed to determine the amount of ApoB in each fraction.
ApoB-48 levels were reduced in all fractions from the REGN1500-treated animals. ApoB-100 levels were similar in the VLDL size range but were reduced in the LDL fractions. Thus, inactivation of ANGPTL3 was associated with changes in both the lipid and protein content of the ApoB-containing lipoproteins.
It remains possible that in the absence of ANGPTL3, LDL precursor particles are cleared more rapidly by LRP1. To determine if LRP1 contributes to the lower lipid levels in ANGPTL3-deficient and TG by 46% and 51%, respectively) in the two lines of mice (Fig. 1A) . REGN1500 also reduced plasma levels of nonesterified fatty acids (NEFA), although the reduction was not significant in this experiment. To determine the effect of inactivating ANGPTL3 on lipoprotein levels in these animals, plasma from each group of mice was fractionated by FPLC (Fig.1B) . Thus, the cholesterol was reduced in all the ApoB-containing lipoprotein fractions as well as in the HDL fractions in both the single and double KO animals ( Fig. 1B ).
Immunological inactivation of ANGPTL3 lowers plasma cholesterol levels in the absence of both
ApoE and LDLR
To determine whether inactivation of ANGPTL3 promotes ApoE-mediated clearance of lipoproteins independently of LDLR or LRP1, we treated Apoe -/-; Ldlr -/-mice with REGN1500.
Inactivation of ANGPTL3 lowered plasma cholesterol levels in Apoe -/-mice ( Fig. 2A) , as was reported previously (22, 23). Similar reductions were observed in Apoe -/-; Ldlr -/-mice. The levels of cholesterol were reduced in the VLDL and LDL fractions, but not in the HDL fractions (where they were already very low) on FPLC analysis (Fig. 2B ).
Immunological inactivation of ANGPTL3 lowers plasma cholesterol levels in the absence of syndecan 1
An alternate pathway for hepatic clearance of LDL precursor particles is by heparan sulfate glycoproteins. These surface glycoproteins, particularly syndecan 1, contribute to clearance of remnant lipoproteins arising from LPL-mediated lipolysis (21, 37) . To determine if ANGPTL3 inactivation accelerates syndecan 1-mediated lipoprotein clearance, we examined the effect of REGN1500 treatment on plasma lipid levels in Sdc1 -/-mice at the end of the feeding cycle. Plasma levels of both cholesterol and TG were increased in the Sdc1 -/-mice, which is consistent with what has been reported previously (21) .
Administration of REGN1500 to Sdc1 -/-mice led to significant decreases in plasma cholesterol and TG levels that were similar to those observed in WT animals (Fig. 3A) .The cholesterol levels were reduced in the VLDL and HDL fractions, which are the major cholesterol-carrying lipoproteins in these mice (Fig.   3B ). The TG content of the VLDL fraction was dramatically reduced by antibody treatment in Sdc1 -/-and in WT mice (85% and 65%, respectively).
Immunologic inactivation of ANGPTL3 does not alter the clearance of exogenous LDL or -VLDL
These data suggest that inactivation of ANGPTL3 does not promote clearance of LDL or its biosynthetic precursors via known lipoprotein receptors or ligands. To directly assess the effect of ANGPTL3 inactivation on LDL clearance, we injected radiolabeled mouse LDL into WT mice treated with either REGN1500 or with control antibody. The decay curves of radiolabeled LDL were superimposable ( We then performed a similar experiment using radiolabeled rabbit -VLDL as a model ApoE-rich lipoprotein in WT mice. The results were similar to those obtained with LDL. No differences were found in the rates of particle clearance between the two groups of mice (Fig. 4B ). To determine if remnants were being cleared by tissues other than the liver, as suggested by Bartelt et al (38) , we measured tissue uptake of radiolabeled -VLDL by quantifying the amount of total and protein-associated (acetone precipitated) radioactivity in tissues (Fig. 4C , top and bottom, respectively). As expected, the tissue with the greatest uptake was the liver. No differences were seen between the two groups of mice in the amount of total protein-associated radioactive counts in liver, heart, muscle, epididymal fat, subcutaneous fat, or brown adipose tissue.
These findings indicate that inactivation of ANGPTL3 does not increase the functional activity of pathways that clear LDL or ApoE-containing lipoproteins either in the liver or in peripheral tissues.
Both immunological and genetic inactivation of ANGPTL3 reduces secretion of VLDL-TG but not VLDL-ApoB-100
One mechanism by which ANGPTL3 inactivation might lower LDL is by decreasing the secretion of VLDL particles by the liver, which would result in fewer VLDL remnants being processed to LDL. To determine if inactivating ANGPTL3 reduces VLDL-TG secretion, we used Triton WR1339 to inhibit LPL in WT and Ldlr -/-mice treated with REGN1500 or with control antibody (28) . The experiment was performed first in WT mice 4 h after refeeding, since ANGPTL3 appears to be most active in the fed state (39) . The rate of accumulation of plasma TG following Triton injection was reduced by 61% (from 12.5 to 4.9 mg TG/dL plasma/min) in REGN1500-treated mice ( REGN1500 also lowered VLDL-TG secretion in fed Ldlr -/-mice (Fig. S2C ).
The consistent reduction in VLDL-TG secretion associated with inactivation of ANGPTL3 in this study contrasts with a previous report (14) in which similar rates of VLDL secretion were observed in KK-San mice, which lack ANGPTL3, and KK mice, which are WT for ANGPTL3. Both studies used the Triton-WR1339 method to assess VLDL production, but Shimizugawa et al. (14) fasted the mice before Triton injection. To determine if differences in nutritional status could account for the differences in the two studies, we repeated the experiment in fasting mice. The effects of REGN1500 on TG accumulation were markedly attenuated when Triton-WR1339 was administered to fasting WT animals (Fig. S2D) .
Whereas, VLDL-TG secretion was reduced 61% in REGN1500-treated fed mice (Fig 5A) , it was only reduced 15% in similarly treated fasted animals (Fig. S2D) .
In mice fed regular chow (4% fat), circulating TG-rich lipoproteins are derived from both the intestine and the liver. To obviate confounding by intestine-derived lipoproteins, we repeated the Triton-WR1339 experiment in WT mice refed with fat-free chow (Fig. S2E ). In these animals the effect of ANGPTL3 inactivation on accumulation of circulating TG was comparable to that observed in animals refed chow.
The reduction in VLDL-TG secretion together with the decrease in plasma levels of VLDL-ApoB and VLDL-cholesterol is consistent with a model in which inactivation of ANGPTL3 decreases the secretion of VLDL particles. To directly test this hypothesis, we administered [ 35 S]-methionine by intravenous injection to WT mice pre-treated either with control IgG or REGN1500 and then measured the appearance of radiolabeled ApoB-100 in the circulation 90 min after Triton-WR1339. VLDL-TG secretion was decreased by REGN1500 treatment (Fig. 6A ), but no differences were seen in the rates of appearance of labeled ApoB-100 or ApoB-48 (Fig. 6B ). Immunoblot analysis of plasma revealed lower levels of both ApoB proteins in the REGN1500-treated animals (Fig. 6C) .
Thus, inactivation of ANGPTL3 reduced the secretion of TG but not of ApoB-100 or ApoB-48.
These data suggest that the lipoproteins secreted after inactivation of ANGPTL3 have less lipid.
Inactivation of ANGPTL3 does not alter the rate of fatty acid synthesis or fatty acid oxidation in mice.
As a first step towards determining if either reduced TG synthesis or increased fatty acid oxidation contributed to the reduction in VLDL-TG secretion in the Angptl3 -/-mice, we compared the hepatic RNA expression profiles of Angptl3 -/-and WT mice liver using whole transcriptome sequencing (RNA-Seq). No major differences were seen in the levels of several mRNAs that encode proteins with key roles in hepatic fatty acid synthesis (ACC, FAS, SCD1), TG lipolysis (ATGL, CGI-58) fatty acid oxidation (CPT-1, CPT-2, ACO), or VLDL catabolism (APOA5, APOC1, APOC2, APOC3, SCARB1, LSR) (Fig. 7A) .
We also measured and compared the rate of synthesis of fatty acids from tritiated water in the livers of Angptl3 -/-mice and littermate controls and found no differences between the two groups (Fig.   7B ).
Finally, we measured fatty acid oxidation in primary hepatocytes isolated from the REGN1500-and control antibody-treated animals using a Seahorse oxygen analyzer. No systematic differences were found in O 2 consumption after treatment with the antibody (Fig. 7C) . As a positive control for the experiment, we added etomoxir, a fatty acid oxidation inhibitor, which reduced O 2 consumption in hepatocytes from both groups of mice.
Inactivation of ANGPTL3 does not affect fatty acid uptake by the liver or other tissues
To determine whether the reduction in TG secretion is caused by reduced delivery of NEFA to the liver, we measured the uptake of 14 C-palmitate and its nonmetabolizable analog, 3 H-bromopalmitate, into tissues of animals treated with REGN1500 or control antibody. Inactivation of ANGPTL3 significantly reduced circulating TG and NEFA levels (Fig. S3A ), but did not affect the tissue distributions of palmitate and bromopalmitate (Fig. S3B) . To determine if the reduction in NEFA levels reflects increased clearance of NEFA, we infused a priming dose followed by a constant infusion of labeled palmitate to achieve a stable level of labeled NEFA in the plasma (Fig. S3C) . No differences were seen in the levels of 14 C counts over the time course of the experiment. Thus, the reduction in circulating NEFA levels after inactivation of ANGPTL3 cannot be explained by increased clearance, and presumably reflects reduced influx of fatty acids into the circulation.
DISCUSSION
In this study we examined the rates of production and clearance of ApoB-containing lipoproteins in mice with antibody-mediated inactivation of ANGPTL3. Our data show that inactivation of ANGPTL3 reduces hepatic secretion of TG in fed mice, which contributes to the low plasma TG levels in these animals. Inactivation of ANGPTL3 also reduced plasma levels of LDL-C and ApoB, despite not reducing hepatic ApoB secretion. These findings imply increased clearance of ApoB-containing lipoproteins in ANGPTL3-deficient animals. We found no increase in the clearance of exogenous LDL or -VLDL in the REGN1500-treated mice, and genetic disruption of the known clearance pathways for Unfortunately, those authors did not report plasma levels of cholesterol for this experiment. Furthermore, careful time-course studies indicate that LPL activity may be as much as 25% of normal in these animals (49). Thus, it is possible that the reduction in TG levels in these mice is due to residual LPL activity.
Further studies will therefore be required to determine the role of LPL in the reductions in plasma cholesterol levels that result from inactivation of ANGPTL3. (53), or in humans with ANGPTL3 deficiency (54) . Therefore it is unlikely that inactivation of ANGPTL3 disrupts VLDL
assembly. An alternative possibility is that increased activity of EL (or another as yet unidentified extracellular lipase) in ANGPTL3-deficient mice may result in hydrolysis of TG from VLDL before the VLDL can acquire enough Triton WR1339 to inhibit lipolysis. Whereas it seems unlikely that the large differences in VLDL-TG secretion observed in this study can be explained by increased intra-hepatic TG hydrolysis in the Angptl3 -/-mice, we cannot formally exclude this possibility.
Whereas inactivation of ANGPTL3 did not decrease ApoB secretion as determined by incorporation of 35S-methionine, plasma levels of ApoB were lower in the REGN1500-treated mice. We hypothesize that this difference arises because the 35S-methionine measures only the newly secreted ApoB, whereas the antibody measures all of the ApoB in plasma, which includes the ApoB present prior to Triton-WR1339 administration plus the newly secreted ApoB. The plasma levels of ApoB are already appreciably lower in the REGN1500-treated mice by the time the triton-WR1339 is injected. Therefore, after the influx of equal amounts of ApoB into the plasma compartment into the two lines, the levels of ApoB will still be lower in the KO animals.
The effect of inactivating ANGPTL3 on VLDL secretion were most apparent in fed animals ( Figure S2 ), as was observed previously for LPL activity (39) . The coupling of ANGPTL3 function to nutritional state is surprising because expression of the protein is only modestly affected by fasting and refeeding. We have proposed that ANGPTL3 acts together with ANGPTL8 to inhibit lipoprotein lipase (26) , and that the activity of the complex is limited by expression ANGPTL8, which is very low in fasting animals and is strongly upregulated by feeding. VLDL-TG secretion is also markedly reduced in fed
Angptl8
-/-mice.
The liver derives fatty acids for VLDL-TG synthesis from intracellular lipid droplets, de novo lipogenesis, lipoprotein remnants, and circulating free fatty acids. In the present study, inactivation of ANGPTL3 did not affect hepatic lipid content or de novo lipogenesis, but circulating free fatty acids, the major substrate for hepatic VLDL-TG, were consistently lower in mice treated with REGN1500 (although the decrease did not reach statistical significance in some experiments ), as reported previously in mice lacking ANGPTL3 (17, 55) . We found no change in the fractional uptake of exogenously administered palmitate or bromopalmitate into the livers of the antibody-treated mice. This finding, together with the decrease in circulating fatty acid concentrations suggests that the total uptake uptake of fatty acids by the liver is decreased by ANGPTL3 inactivation. The decrease in hepatic TG secretion in animals lacking ANGPTL3 may therefore be due to a decrease in the supply of free fatty acids to the liver. This hypothesis is not consistent with data from Zhang et al. (56) who showed that a 6-hour infusion of 6mM oleate into mice altered secretion of ApoB, but not TG.
The effects on plasma lipids of inactivating ANGPTL3 resemble those observed in mice lacking ApoC3 (57) . Like ANGPTL3, ApoC3 has been studied primarily as a circulating inhibitor of LPL activity. However a recent report that inactivation of ApoC3 using an antisense inhibitor markedly reduced plasma levels of TG in patients with LPL deficiency (58) confirmed a broader role for ApoC3 in human lipoprotein metabolism. The antibody described in this report will allow similar studies to be undertaken for ANGPTL3. synchronized for 3 days (fasting: 5:00pm-7:00 am and feeding: 7:00 am-5:00 pm). On day 4, mice were refed at 7:00 am and injected at 9:00 am with either a control antibody or REGN1500 (10 mg/kg) (n=5 male mice/group, 10 weeks old). Two hours after the injection, Triton WR1339 (500 mg/kg) was injected into the tail vein. Blood samples were drawn from the tail veins at the indicated time points and then the mice were sacrificed and blood collected. Plasma TG levels were measured enzymatically. Plasma collected at the 90 min time point was pooled and fractionated by FPLC as described in the Methods and TG and cholesterol were measured enzymatically in each fraction. The total TG and cholesterol content of the pooled VLDL fractions (7, 8 and 9) are shown below. (B）ApoB-100 and ApoB48 protein levels in the pooled VLDL fractions (7,8 and 9) were assayed by immunoblotting (top) and quantified using ImageJ. (A) Messenger RNA levels of genes involved in fatty acid synthesis or oxidation. Livers were collected from refed mice used in the experiment shown in Fig. S2A . Total RNA was extracted and subjected to whole transcriptome shotgun sequencing using an Illumina 2500 Hi-Seq as described previously (26) . 
